Rutherrin (TLD1433/transferrin) / Theralase - LARVOL DELTA

Ruvidar®-An Effective Anti-Herpes Simplex Virus Agent. (PubMed, Viruses) - "Currently, effective FDA approved anti-herpetic drugs include acyclovir and later-generation derivatives (valacyclovir and famciclovir), which inhibit viral DNA synthesis...In these experiments, we evaluated the ability of Ruvidar® to restrict HSV-1 replication in Vero cells, both by itself and in combination with acyclovir and metformin in the absence of light activation to mimic deep tissue...We also discovered additive and synergistic anti-HSV-1 effects when combinational therapy was tested. Ruvidar® also restricted HSV-1 replication in human U251 glioblastoma astrocytoma cells, remained highly effective against acyclovir-resistant HSV-1 mutants, and protected infected cells from virus-induced cytopathology."

Journal • Astrocytoma • Brain Cancer • Glioblastoma • Herpes Simplex • Oncology • Solid Tumor

Rutherrin® Activated by Radiation Therapy Induces Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models (ASTRO 2025) - "Rutherrin® activated by RT enhanced tumor regression, immune memory response, and overcame resistance mechanisms versus RT alone. By enhancing ROS-mediated cytotoxicity and modulating drug efflux, Rutherrin® presents a powerful approach to improve local tumor control and systemic immunity. These findings support clinical investigation of Rutherrin® as a transformative adjunct to RT for improved cancer treatment."

Preclinical • Brain Cancer • Glioblastoma • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Solid Tumor

Theralase(R) Closes Non-Brokered Private Placement (ACCESSWIRE) - "Theralase Technologies Inc...is pleased to announce that it has successfully closed a non-brokered private placement offering ('Offering') of units ('Units'). On closing, the Corporation issued an aggregate of 2,221,334 Units at a price of $CAN 0.30 per Unit for aggregate gross proceeds of approximately $CAN 666,400....The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder Cancer ('NMIBC') clinical study currently underway, preclinical research and development of Rutherrin, working capital and general corporate purposes."

Financing • Bladder Cancer

Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer (ACCESSWIRE) - "Theralase...is pleased to announce that it's lead drug formulation, Rutherrin, has demonstrated an ability to provide a significant enhancement of Cisplatin efficacy in chemotherapy resistant Non-Small Cell Lung Cancer...In further experimentation, mice were treated with Cisplatin...in a control group versus Cisplatin combined with Rutherrin in an active group...The mice treated with Cisplatin and Rutherrin demonstrated a significantly higher (p<0.001) enhancement of cisplatin efficacy and a significantly higher (p < 0.001) increase in overall mouse survival. This survival is analogous to a 1 year overall survival in humans and is significant due to the aggressiveness of the LLCI orthotopic model....'Pending sufficient capitalization and completion of a Good Laboratory Practice....toxicology analysis for Rutherrin, Theralase plans to commence clinical studies for brain cancer, lung cancer and various blood-based cancers in 2025.'"

New trial • Preclinical • Brain Cancer • CNS Tumor • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement (ACCESSWIRE) - "Theralase Technologies Inc...is pleased to announce that it has successfully closed its first tranche of a Non-Brokered Private Placement ('NBPP') offering ('Offering') of units...On closing, the Corporation issued an aggregate of 3,522,729 Units at a price of $CAN 0.22 per Unit for aggregate gross proceeds of $CAN 775,000....The Company plans to use the proceeds of the financing to further the Phase II Non-Muscle Invasive Bladder Cancer ('NMIBC') clinical study currently underway, preclinical research and development of Rutherrin, working capital and general corporate purposes."

Financing • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically (ACCESSWIRE) - "Theralase Technologies Inc...is pleased to announce that it's lead drug formulation, Rutherrin, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer ('NSCLC') animal model....The mice treated with x-ray activated Rutherrin demonstrated up to a 4-fold reduced tumor progression, based on Computerized Tomography ('CT') scan assessment of tumor volumes....These results demonstrate that animals treated with a combination of Rutherrin and radiation therapy showed an increase in median survival from 26 to 35 days, versus radiation only. In scientific publications, mouse survival of 9 days has been equated to the equivalent of 1 year survival in humans, but more importantly, is that one animal treated with the x-ray activated Rutherrin (which had a positive lung tumor verified by CT scan) demonstrated a complete response and is now considered cancer free."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Rutherrin(R) Increases Efficacy of Chemotherapy (ACCESSWIRE) - "Theralase Technologies Inc...is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin has been proven effective in increasing the efficacy of chemotherapy and reducing multidrug resistance...treatment with Rutherrin significantly enhanced the retention of all tested chemotherapeutic drugs, presumably through the inhibition of the ABC transporter efflux pump, resulting in higher intracellular drug accumulation, which would increase exposure of the cancer cells to the respective chemotherapy and consequently improve overall treatment efficacy....addition of Rutherrin significantly increased the cancer cell kill for all tested chemotherapeutic drugs, suggesting a universal effect of Rutherrin on chemotherapeutic drugs in their destruction of cancer cells, rendering the cancer cells more susceptible to chemotherapy."

Preclinical • Brain Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Theralase Releases Q222 Interim Financial Statements (GlobeNewswire) - "The Company has demonstrated significant anti-cancer efficacy of Rutherrin®, when activated by laser light or radiation treatment across numerous preclinical models; including: Glio Blastoma Multiforme ('GBM') and Non-Small Cell Lung Cancer ('NSCLC'). The Company has commenced Non - Good Laboratory Practices ('GLP') toxicology studies with Rutherrin® in animals to help determine the maximum recommended human dose of the drug, when administered systemically into the human body, via intravenous injections. Theralase plans to commence GLP toxicology studies in animals in 4Q2022."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Theralase Release FY2020 Audited Financial Statements (Issuer Direct) - “The Company has demonstrated significant anti-cancer efficacy of Rutherrin®, when activated by laser light or radiation treatment across numerous preclinical models; including: Glio Blastoma Multiforme (‘GBM’) and Non-Small Cell Lung Cancer (‘NSCLC’)…Theralase plans to commence GLP toxicology studies in animals in 2021.”

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Thoracic Cancer